Recent update on comprehensive therapy for advanced hepatocellular carcinoma

World J Gastrointest Oncol. 2021 Aug 15;13(8):845-855. doi: 10.4251/wjgo.v13.i8.845.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The treatment methods for HCC are diverse, mainly including surgical resection, ablation, and liver transplantation. The curative effect can be achieved only for early stage HCC, and it is easy to recur and metastasize after surgery, with a 5-year recurrence rate as high as 70%. Most patients with HCC are in the middle and advanced stage at the time of diagnosis and lose the chance of surgical resection. In recent years, with the in-depth study of the pathogenesis of HCC and the progress of medical science and technology, the systemic treatment of advanced HCC has made a breakthrough. At present, multidisciplinary comprehensive treatment including targeted therapy and immunotherapy has become an effective strategy and inevitable trend for the treatment of advanced HCC. Combined therapy has greatly improved the prognosis of HCC patients and opened up a new milestone in the treatment of this malignancy. In this article, we focus on the treatment progress of advanced HCC to further guide clinical practice.

Keywords: Comprehensive therapy; Hepatocellular carcinoma; Immunotherapy; Local treatment; Multidisciplinary therapy; Targeted therapy.

Publication types

  • Review